Flare Therapeutics is a clinical-stage biotechnology company exclusively focused on drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class. The company's development portfolio targeting transcription factors involved in oncology leverages Flare Therapeutics' integrated discovery platform of capabilities that identifies novel validated ligands to the undrugged proteome.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/09/26	$85,000,000	Series C	Agent Capital Boxer Capital Casdin Capital Eli Lilly Ventures Eventide Asset Management GordonMD Global Investments Invus Nextech Invest Novartis Venture Funds Pfizer Venture Investments Third Rock Ventures	undisclosed